All In Biotech

Drug Trial Radar · NCT07750041

A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Coloretal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Aug 30, 2026

Primary completion

Dec 31, 2027

Study completion Aug 30, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.

Conditions

  • Unresectable Advanced or Metastatic Colorectal Cancer

Interventions

  • SYS6090 (Fixed Dose Level A) + bevacizumabDrug

    Participants will receive intravenous SYS6090 at fixed dose level A combined with intravenous bevacizumab, administered per cycle schedule specified in study protocol, for advanced/palliative unresectable pMMR/MSS colorectal cancer.

  • SYS6090 (Fixed Dose Level B ) + bevacizumabDrug

    Participants will receive intravenous SYS6090 at fixed dose level B plus intravenous bevacizumab per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

  • SYS6090 RP2D + bevacizumab +mFOLFOX6Drug

    Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab combined with standard mFOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin, fluorouracil), administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

  • SYS6090 RP2D + bevacizumabDrug

    Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab, administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

  • RegorafenibDrug

    Oral regorafenib monotherapy as standard control for metastatic pMMR/MSS colorectal cancer.

  • SYS6090 PR2D+ bevacizumab + FOLFOXIRIDrug

    Participants will receive intravenous SYS6090at RP2D plus intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.

  • bevacizumab + FOLFOXIRIDrug

    Participants will receive intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D), Safety and TolerabilityTime frame: up to approximately 3 years after the first enrollment
  2. Objective Response Rate (ORR) assessed per RECIST v1.1Time frame: up to approximately 3 years after the first enrollment
  3. Progression-Free Survival (PFS) assessed per RECIST v1.1Time frame: up to approximately 3 years after the first enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fujian, Fuzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.